You have no items in your shopping cart.
BDTX-1535 is an orally bioavailable, brain-penetrating, mutation-selective, EGFR inhibitor with potential antitumor activity.
BDTX-1535 is a fourth-generation EGFR inhibitor that overcomes resistance to Osimertinib, the standard of care for EGFR-mutant non–small cell lung cancer (NSCLC). BDTX-1535 works well in NSCLC carrying C797S.
Importantly, BDTX-1535 can cross the blood-brain barrier and potentially treat CNS metastases in NSCLC. BDTX-1535 is also highly potent in EGFR-mutant glioblastoma cell lines and mouse models.
Synonym: BDTX-1535; BDTX1535; BDTX 1535
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email firstname.lastname@example.org if you have any requirements.